01 2BRISTOL
02 38GILEAD SCIENCES INC
03 14JANSSEN PRODS
01 310039718*PED
02 27176220
03 27176220*PED
04 27390791
05 17390791*PED
06 27635704
07 27635704*PED
08 17700645
09 108148374
10 38148374*PED
11 28633219
12 38754065
13 28981103
14 39296769
15 29891239
16 510039718
17 110786518
18 28633219*PED
19 18754065*PED
20 28981103*PED
21 19296769*PED
22 29891239*PED
01 25Y
02 29Blank
01 34Y
02 20Blank
01 12025-01-07
02 12025-04-17
03 12025-07-07
04 22026-08-27
05 42026-10-26
06 12026-12-26
07 22027-02-27
08 42027-04-26
09 122029-09-03
10 52030-03-03
11 22030-04-30
12 22030-10-30
13 62032-08-15
14 52032-10-06
15 22033-02-15
16 32033-04-06
17 12038-07-19
Patent Expiration Date : 2029-09-03
ATAZANAVIR SULFATE; COBICISTAT
US Patent Number : 8148374
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 206353
Patent Use Code : U-1279
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2032-10-06
ATAZANAVIR SULFATE; COBICISTAT
US Patent Number : 10039718
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 206353
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-10-06
Patent Expiration Date : 2030-04-30
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 8633219
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2030-04-30
Patent Expiration Date : 2026-10-26
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 7635704
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2026-10-26
Patent Expiration Date : 2029-09-03
US Patent Number : 8148374
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203094
Patent Use Code : U-1279
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2029-09-03
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 8148374
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-1279
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2032-08-15
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 8754065
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2032-08-15
Patent Expiration Date : 2032-08-15
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 9296769
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2032-08-15
Patent Expiration Date : 2029-09-03
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 9891239
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2030-04-30
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 8633219
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2030-04-30
